Related Experiment Videos
Matrix metalloproteinases and tissue valve degeneration
M Bracher1, D Simionescu, A Simionescu
1Department of Cardiothoracic Surgery, Cape Heart Centre, University of Cape Town Medical School, Cape Town, South Africa.
Journal of Long-Term Effects of Medical Implants
|March 30, 2002
Summary
Bioprosthetic heart valves degrade structurally within 15 years due to proteolytic enzymes like matrix metalloproteinases (MMPs). This degradation, combined with mechanical stress, leads to bioprosthetic valve failure.
Area of Science:
- Biomaterials Science
- Cardiovascular Research
- Biochemistry
Background:
- Bioprosthetic heart valves are widely used for valve replacement.
- Over 50% of these valves fail within 15 years due to structural deterioration.
- Understanding valve degeneration is crucial for improving longevity.
Purpose of the Study:
- To review the role of proteolytic degradation in bioprosthetic aortic valve degeneration.
- To highlight the contribution of matrix metalloproteinases (MMPs) to valve failure.
- To synthesize current knowledge on factors contributing to bioprosthetic valve failure.
Main Methods:
- Literature review of studies on bioprosthetic heart valve degeneration.
- Analysis of the mechanisms of proteolytic degradation.
- Examination of the role of matrix metalloproteinases (MMPs).
Main Results:
- Proteolytic degradation significantly contributes to the structural deterioration of bioprosthetic valves.
- Both intrinsic and host-derived proteolytic activities are implicated in valve failure.
- Mechanical stress exacerbates valve degeneration.
Conclusions:
- Proteolytic degradation, particularly by MMPs, is a key factor in bioprosthetic aortic valve failure.
- The interplay between proteolytic activity and mechanical stress accelerates valve degeneration.
- Further research into mitigating proteolytic degradation is needed to enhance bioprosthetic valve durability.